ArticleJAMA network open2026
Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of maternal RSV vaccination against infant lower respiratory tract infections: a systematic review and meta-analysis.Frontiers in public health · 2026Pooled it
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: The bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine was licensed in the US in September 2023 to prevent RSV-associated lower respiratory tract disease (LRTD) in infants via maternal immunization. Clinical data on vaccine effectiveness are limited. Objective: To estimate the effectiveness of maternal RSVpreF vaccination against hospitalization for RSV-associated acute respiratory illness (ARI) and LRTD among infants 90 days or younger during the first 2 postlicensure RSV seasons. Design, Setting, and Participants: This retrospective case-control study (Effectiveness of ABRYSVO Maternal Respiratory Syncytial Virus Vaccine Against RSV in Infants in Western Pennsylvania study) using a test-negative design was conducted within a single health system in western Pennsylvania during the 2023-2024 and 2024-2025 RSV seasons. The analysis included infants 90 days or younger born between October 1, 2023, and April 15, 2024, or between September 1, 2024, and April 30, 2025, who were hospitalized with ARI and tested for RSV using nucleic acid amplification or rapid antigen testing. Exposure: Maternal RSVpreF vaccination administered at gestational age between 32 weeks 0 to 7 days and 36 weeks 6 to 7 days and at least 14 days before delivery. Main Outcomes and Measures: The primary outcome was RSV-associated ARI requiring hospitalization. The secondary outcome was RSV-associated LRTD requiring hospitalization. Vaccine effectiveness was estimated as (1 - Adjusted Odds Ratio) × 100% comparing the odds of maternal RSVpreF vaccination among RSV-positive infants (cases) vs RSV-negative infants (controls) using multivariable logistic regression. Results: Among 274 included infants (83 with RSV and 191 controls), the mean (SD) age at admission was 29.5 (21.1) days; 143 infants (52.2%) were male. Among these, 11 of 83 infants with RSV (13.3%) and 71 of 191 controls (37.2%) were born to RSVpreF-vaccinated individuals. Vaccine effectiveness was estimated to be 67.6% (95% CI, 33.2%-85.4%) against RSV-associated ARI hospitalization and 69.0% (95% CI, 25.5%-88.0%) against RSV-associated LRTD hospitalization from 0 through 90 days of age. Among infants aged 0 to 30 days, vaccine effectiveness against RSV-associated ARI hospitalization was estimated to be 74.2% (95% CI, 25.4%-93.0%). Conclusions and Relevance: Maternal RSVpreF vaccination was associated with protection against RSV-associated ARI and LRTD hospitalization among infants 90 days or younger. These findings provide early clinical evidence supporting the effectiveness of maternal RSVpreF vaccination in preventing RSV-associated hospitalization in infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.